Top menu spacer

Print bar spacer Register | Logon

Print bar spacerSite map Site map

XELODA – AT A GLANCE
XELOX provides equivalent efficacy compared with FOLFOX in patients with metastatic colorectal cancer. Data released at the 2007 ASCO Gastrointestinal Cancers Symposium show non-inferiority.
Xeloda posters from the 2007 Gastrointestinal Cancers Symposium (ASCO GI) now available to view
First efficacy and safety results from XELOX-1 (NO16966) phase III trial in mCRC presented at ESMO presidential symposium.



NEWSROOM
Colorectal cancer patients treated with XELOX spend over 160 fewer hours receiving intravenous treatment. Oral Xeloda combination effective and time-saving.

Basel, Switzerland, 04 June 2007

XELOX provides equivalent efficacy compared with FOLFOX in patients with metastatic colorectal cancer

Data released at the 2007 ASCO Gastrointestinal Cancers Symposium have shown that XELOX (Xeloda plus oxaliplatin) is non-inferior to the current standard treatment, FOLFOX, in patients with metastatic colorectal cancer (mCRC).
CASE STUDIES
Review some of the issues you need to consider when managing this patient: A 73-year-old postmenopausal woman with primary breast cancer.
 
STAGING MANUAL
Download two chapters from the AJCC Cancer Staging Manual to your PDA.